Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-08-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：独立董事关于第三届董事会第十六次会议相关事项的独立意见
Regulatory Filings
2023-08-25 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司调整募集资金投资项目拟投入募集资金金额的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the adjustment of the amount of funds raised to be invested in specific projects by Shanghai Medicilon Inc. It references regulatory approvals, fundraising amounts, adjustments to investment projects, and opinions from the board, independent directors, and supervisory board. The content focuses on the management and use of raised funds, compliance with regulatory guidelines, and the approval process. This is a typical capital/financing update related to the use and adjustment of proceeds from a specific fundraising event. The document length is about 3,000 characters, which is substantive and not a mere announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-25 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from a securities company (广发证券股份有限公司) acting as a sponsor institution, providing an opinion on the use of part of idle raised funds by Shanghai Medicilon Inc. for cash management. It includes regulatory references, detailed descriptions of the raised funds, investment purposes, types of investment products, investment limits, decision-making processes, risk control measures, and approvals by the board, independent directors, and supervisory board. The document is not a brief announcement but a comprehensive verification and opinion report related to the use of raised funds. It is not an annual or interim financial report, nor an earnings release or a simple announcement. It is a regulatory compliance and verification report related to fundraising and cash management. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit into other specific categories like Capital/Financing Update (CAP) or Audit Report (AR). The document length is 4745 characters, which is substantial and contains detailed content, not just an announcement of a report. Therefore, the classification is Regulatory Filings (RNS).
2023-08-25 Chinese
美迪西：关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for the company Shanghai Medicilon Biopharmaceutical Co., Ltd. It details the replacement of a sponsor representative and includes a brief resume of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes at the board level. This is a regulatory announcement about sponsor representative changes related to IPO and stock issuance supervision, which does not fit into categories like Annual Report, Interim Report, or Management Information. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-25 Chinese
美迪西：关于参加2023年半年度制药及生物制品行业集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. about participating in the 2023 semi-annual pharmaceutical and biological products industry collective performance briefing. It mentions the date and format of the meeting (video and online text interaction), the participants, and how investors can submit questions. It also references that the company's 2023 semi-annual report and summary have already been disclosed on the Shanghai Stock Exchange website. The document does not contain actual financial statements or detailed financial analysis but serves as a notice about the upcoming investor presentation event. The document length is short (1409 characters), and it primarily announces the event rather than providing the report itself. Therefore, it fits best as an Investor Presentation (IP) announcement rather than the report itself or a report publication announcement (RPA).
2023-08-25 Chinese
美迪西：关于签署募集资金专户存储三方监管协议及四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Medicilon Inc. regarding the signing of three-party and four-party supervision agreements for the storage of raised funds in special accounts. It details the amount of funds raised, the bank accounts opened for these funds, and the regulatory compliance and supervisory responsibilities related to the use of these funds. The document references the approval from the China Securities Regulatory Commission for a private placement of shares and includes details about the capital raised and its management. There are no financial statements or detailed financial performance data included, nor is this a transcript, report, or presentation. The document is primarily about the management and regulatory oversight of capital raised through a share issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is about 4618 characters, which is sufficient to be a full announcement rather than a brief notice or report publication announcement. Therefore, the correct classification is CAP with high confidence.
2023-08-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.